Diabetes (type 1 and 2) - inhaled insulin

Summary

In January 2008, Pfizer ceased production of its inhaled insulin product Exubera. NICE technology appraisal 113 on inhaled insulin for diabetes (types I and II) has therefore been made obsolete.

Pfizer have been letting doctors know that they should begin moving their patients off Exubera and onto other medicines that control high blood sugar levels. If you are worried about how you should control your blood sugar levels as a result of this announcement, you should contact your doctor as soon as possible to discuss your options for other blood sugar lowering medications.

25 January 2008

Documents

For healthcare professionals

• TA113 Diabetes (type 1 and 2) - inhaled insulin: quick reference guide
• TA113 Diabetes (type 1 and 2) - inhaled insulin: guidance (MS word format)
• TA113 Diabetes (type 1 and 2) - inhaled insulin: guidance

For patients, carers and the public

• TA113 Diabetes (type 1 and 2) - inhaled insulin: understanding NICE guidance (MS word format)
• TA113 Diabetes (type 1 and 2) - inhaled insulin: understanding NICE guidance

Background information

• 2006/059 New NICE guidance increases insulin options for some people with diabetes

Implementing this guidance

Any further information NICE has produced to help the NHS implement this guideline locally is linked to below:

• Diabetes (type 1 and 2) - inhaled insulin: Costing template
• TA113 Diabetes (type 1 and 2) - inhaled insulin: Audit criteria